Skip to Content
MilliporeSigma
  • Genetic deficiency of the mitochondrial protein PGAM5 causes a Parkinson's-like movement disorder.

Genetic deficiency of the mitochondrial protein PGAM5 causes a Parkinson's-like movement disorder.

Nature communications (2014-09-16)
Wei Lu, Senthilkumar S Karuppagounder, Danielle A Springer, Michele D Allen, Lixin Zheng, Brittany Chao, Yan Zhang, Valina L Dawson, Ted M Dawson, Michael Lenardo
ABSTRACT

Mitophagy is a specialized form of autophagy that selectively disposes of dysfunctional mitochondria. Delineating the molecular regulation of mitophagy is of great importance because defects in this process lead to a variety of mitochondrial diseases. Here we report that mice deficient for the mitochondrial protein, phosphoglycerate mutase family member 5 (PGAM5), displayed a Parkinson's-like movement phenotype. We determined biochemically that PGAM5 is required for the stabilization of the mitophagy-inducing protein PINK1 on damaged mitochondria. Loss of PGAM5 disables PINK1-mediated mitophagy in vitro and leads to dopaminergic neurodegeneration and mild dopamine loss in vivo. Our data indicate that PGAM5 is a regulator of mitophagy essential for mitochondrial turnover and serves a cytoprotective function in dopaminergic neurons in vivo. Moreover, PGAM5 may provide a molecular link to study mitochondrial homeostasis and the pathogenesis of a movement disorder similar to Parkinson's disease.

MATERIALS
Product Number
Brand
Product Description

USP
Levodopa, United States Pharmacopeia (USP) Reference Standard
Levodopa, European Pharmacopoeia (EP) Reference Standard
Supelco
Levodopa, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
4-tert-Octylphenol monoethoxylate solution, 10 μg/mL in acetone, analytical standard
Sigma-Aldrich
Carbonyl cyanide 3-chlorophenylhydrazone, ≥97% (TLC), powder
Sigma-Aldrich
MISSION® esiRNA, targeting human PGAM5
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Pgam5
Sigma-Aldrich
3,4-Dihydroxy-L-phenylalanine, ≥98% (TLC)